Genetic basis of polycystic ovary syndrome

References

• Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab.85, 2434–2438 (2000).
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Kouli CR, Bergiele AT et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab.84, 4006–4011 (1999).
   PubMed Web of Science ®Google Scholar
• Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin. Endocrinol. (Oxf.)51, 779–786 (1999).
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod.19, 41–47 (2004).
   PubMed Web of Science ®Google Scholar
• Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Polycystic Ovary Syndrome. Dunaif A, Haseltine FP, Merriam GR (Eds). Blackwell Scientific, MA, USA 377–384 (1992).
   Google Scholar
• Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J. Clin. Endocrinol. Metab.91, 2100–2104 (2006).
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome. N. Engl. J. Med.333, 853–861 (1995).
   PubMed Web of Science ®Google Scholar
• Sam S, Coviello AD, Sung YA, Legro RS, Dunaif A. Metabolic phenotype in the brothers of women with polycystic ovary syndrome. Diabetes Care31, 1237–1241 (2008).
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Carpentier AC. Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia50, 2424–2432 (2007).
   PubMed Web of Science ®Google Scholar
• Recabarren SE, Smith R, Rios R et al. Metabolic profile in sons of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.93, 1820–1826 (2008).
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Bukan N, Ersoy R et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum. Reprod.20, 2414–2420 (2005).
   PubMed Web of Science ®Google Scholar
• Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin. Endocrinol. (Oxf.)65, 137–145 (2006).
   PubMed Web of Science ®Google Scholar
• Lee YS. The role of genes in the current obesity epidemic. Ann. Acad. Med. Singap.38, 45–43 (2009).
   PubMed Web of Science ®Google Scholar
• Barber TM, McCarthy MI, Franks S, Wass JA. Metabolic syndrome in polycystic ovary syndrome. Endokrynol. Pol.58, 34–41 (2007).
   PubMedGoogle Scholar
• Berneis K, Rizzo M, Lazzaroni V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.92(1), 186–189 (2007).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.91, 48–53 (2006).
   PubMed Web of Science ®Google Scholar
• Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet. Gynecol.106, 131–137 (2005).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism52, 908–915 (2003).
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 1929–1935 (2005).
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. (Oxf.)52, 595–600 (2000).
   PubMed Web of Science ®Google Scholar
• Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 4797–4802 (2005).
   PubMed Web of Science ®Google Scholar
• Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin. Endocrinol. (Oxf.)66, 513–517 (2007).
   PubMed Web of Science ®Google Scholar
• Hirschberg AL. Polycystic ovary syndrome, obesity and reproductive implications. Womens Health (Lond. Engl.)5, 529–540 (2009).
   PubMedGoogle Scholar
• Cocksedge KA, Li TC, Saravelos SH, Metwally M. A reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage. Reprod. Biomed. Online17, 151–160 (2008).
   PubMed Web of Science ®Google Scholar
• Koivunen R, Pouta A, Franks S et al. Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. Hum. Reprod.23, 2134–2139 (2008).
   PubMed Web of Science ®Google Scholar
• Franks S, Gharani N, Waterworth D et al. Current developments in the molecular genetics of the polycystic ovary syndrome. Trends Endocrinol. Metab.9, 51–54 (1998).
   Google Scholar
• Urbanek M. The genetics of the polycystic ovary syndrome. Nat. Clin. Pract. Endocrinol. Metab.3, 103–111 (2007).
   PubMedGoogle Scholar
• Simoni M, Tempfer CB, Destenaves B, Fauser BC. Functional genetic polymorphisms and female reproductive disorders: part I: polycystic ovary syndrome and ovarian response. Hum. Reprod. Update14, 459–484 (2008).
   PubMed Web of Science ®Google Scholar
• Balen AH, Conway GS, Kaltsas G et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum. Reprod.10, 2107–2111 (1995).
   PubMed Web of Science ®Google Scholar
• Kiddy DS, Hamilton-Fairley D, Bush A et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.)36, 105–111 (1992).
   PubMed Web of Science ®Google Scholar
• Frayling TM, Timpson NJ, Weedon MN et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science316, 889–894 (2007).
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes38, 1165–1174 (1989).
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev.18, 774–800 (1997).
   PubMed Web of Science ®Google Scholar
• Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog. Horm. Res.56, 295–308 (2001).
   PubMedGoogle Scholar
• Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.80, 2586–2593 (1995).
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann D, Legro RS et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab.86, 1626–1632 (2001).
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum. Reprod.15, 1266–1274 (2000).
   PubMed Web of Science ®Google Scholar
• Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J. Clin. Endocrinol. Metab.83, 3984–3991 (1998).
   PubMed Web of Science ®Google Scholar
• Nestler JE, Powers LP, Matt DW et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab.72, 83–89 (1991).
   PubMed Web of Science ®Google Scholar
• Barber TM, Bennett AJ, Groves CJ et al. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia51, 1153–1158 (2008).
   PubMed Web of Science ®Google Scholar
• Attaoua R, Ait El Mkadem S, Radian S et al.FTO gene associates to metabolic syndrome in women with polycystic ovary syndrome. Biochem. Biophys. Res. Commun.373, 230–234 (2008).
   PubMed Web of Science ®Google Scholar
• Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and Type 2 diabetes mellitus. Curr. Diabetes Rev.3, 33–39 (2007).
   PubMedGoogle Scholar
• San-Millan JL, Escobar-Morreale HF. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case–control study followed by systematic review and meta-analysis of existing evidence. Clin. Endocrinol. (Oxf.)72, 383–392 (2010).
   PubMed Web of Science ®Google Scholar
• Hahn S, Haselhorst U, Tan S et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes114, 577–583 (2006).
   PubMed Web of Science ®Google Scholar
• Mahmoudi T. Genetic variation in the vitamin D receptor and polycystic ovary syndrome risk. Fertil. Steril.92(4), 1381–1383 (2009).
   PubMed Web of Science ®Google Scholar
• Atiomo WU, Fox R, Condon JE et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin. Endocrinol. (Oxf.)52, 487–492 (2000).
   PubMedGoogle Scholar
• Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur. J. Endocrinol.150, 793–798 (2004).
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Shaikh N, Khavale S et al. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome. Eur. J. Endocrinol.160, 855–862 (2009).
   PubMed Web of Science ®Google Scholar
• Grant SF, Thorleifsson G, Reynisdottir I et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of Type 2 diabetes. Nat. Genet.38, 320–323 (2006).
   PubMed Web of Science ®Google Scholar
• Zeggini E, McCarthy MI. TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia50(1), 1–4 (2007).
   PubMed Web of Science ®Google Scholar
• Groves CJ, Zeggini E, Minton J et al. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a Type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes55, 2640–2644 (2006).
   PubMed Web of Science ®Google Scholar
• Florez J, Burtt N, de Bakker P et al. Haplotype structure and genotype–phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes53, 1360–1368 (2004).
   PubMed Web of Science ®Google Scholar
• Rutter GA, Parton LE. The β-cell in Type 2 diabetes and in obesity. Front. Horm. Res.36, 118–134 (2008).
   Google Scholar
• Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J. Clin. Invest.96, 520–527 (1995).
   PubMed Web of Science ®Google Scholar
• Dunaif A, Finegood DT. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab.81, 942–947 (1996).
   PubMed Web of Science ®Google Scholar
• Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease. J. Clin. Endocrinol. Metab.86, 66–71 (2001).
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Bendlova B, Hill M, Vankova M, Vondra K, Starka L. Insulin sensitivity and β-cell function in women with polycystic ovary syndrome. Diabetes Care25, 1217–1222 (2002).
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG. β-cell function: a key pathological determinant in polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 310–315 (2005).
   PubMed Web of Science ®Google Scholar
• Rice S, Christoforidis N, Gadd C et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum. Reprod.20, 373–381 (2005).
   PubMed Web of Science ®Google Scholar
• Barber TM, Bennett AJ, Groves CJ et al. Disparate genetic influences on polycystic ovary syndrome (PCOS) and Type 2 diabetes revealed by a lack of association between common variants within the TCF7L2 gene and PCOS. Diabetologia50, 2318–2322 (2007).
   PubMed Web of Science ®Google Scholar
• Christopoulos P, Mastorakos G, Gazouli M et al. Genetic variants in TCF7L2 and KCNJ11 genes in a Greek population with polycystic ovary syndrome. Gynecol. Endocrinol.24, 486–490 (2008).
   PubMed Web of Science ®Google Scholar
• Biyasheva A, Legro RS, Dunaif A, Urbanek M. Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2. J. Clin. Endocrinol. Metab.94, 2617–2625 (2009).
   PubMed Web of Science ®Google Scholar
• Barber TM, Bennett AJ, Gloyn AL et al. Relationship between E23K (an established Type II diabetes-susceptibility variant within KCNJ11), polycystic ovary syndrome and androgen levels. Eur. J. Hum. Genet.15, 679–684 (2007).
   Google Scholar
• Powell BL, Haddad L, Bennett A et al. Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J. Clin. Endocrinol. Metab.90, 2988–2993 (2005).
   Google Scholar
• Pugliese A, Miceli D. The insulin gene in diabetes. Diabetes Metab. Res. Rev.18, 13–25 (2002).
   PubMed Web of Science ®Google Scholar
• Waterworth DM, Bennett ST, Gharani N et al. Linkage association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet349, 986–990 (1997).
   PubMed Web of Science ®Google Scholar
• Urbanek M, Legro RS, Driscoll DA et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc. Natl Acad. Sci. USA96, 8573–8578 (1999).
   PubMed Web of Science ®Google Scholar
• Calvo RM, Telleria D, Sancho J, San Millan JL, Escobar-Morreale HF. Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women. Fertil. Steril.77, 666–668 (2002).
   PubMed Web of Science ®Google Scholar
• Simpson ER. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol.86, 225–230 (2003).
   PubMed Web of Science ®Google Scholar
• Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity – a site-specific role for 17β-hydroxysteroid dehydrogenase Type 5. J. Endocrinol.183, 331–342 (2004).
   PubMed Web of Science ®Google Scholar
• Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5 α-reductase activity in polycystic ovary syndrome. Lancet335, 431–433 (1990).
   PubMed Web of Science ®Google Scholar
• Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol. Cell. Endocrinol.163, 49–52 (2000).
   PubMed Web of Science ®Google Scholar
• Vassiliadi DA, Barber TM, Hughes BA et al. Increased 5 α-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.94(9), 3558–3566 (2009).
   PubMed Web of Science ®Google Scholar
• Gaasenbeek M, Powell BL, Sovio U et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J. Clin. Endocrinol. Metab.89, 2408–2413 (2004).
   PubMedGoogle Scholar
• Gharani N, Waterworth DM, Batty S et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum. Mol. Genet.6, 397–402 (1997).
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, Tsianateli TC, Kouli CR. Microsatellite polymorphism (TTTTA)(n) at -528 base pairs of gene CYP11α influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil. Steril.73, 735–741 (2000).
   PubMedGoogle Scholar
• Daneshmand S, Weitsman SR, Navab A, Jakimiuk AJ, Magoffin DA. Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17α-hydroxylase/C(17–20) lyase promoters. Fertil. Steril.77, 274–280 (2002).
   PubMedGoogle Scholar
• Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R. Variants in the 5α-reductase Type 1 and Type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J. Clin. Endocrinol. Metab.91, 4085–4091 (2006).
   PubMed Web of Science ®Google Scholar
• Petry CJ, Ong KK, Michelmore KF et al. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum. Reprod.20, 1837–1843 (2005).
   PubMed Web of Science ®Google Scholar
• Stanworth RD, Kapoor D, Channer KS, Jones TH. Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with Type 2 diabetes. Eur. J. Endocrinol.159, 739–746 (2008).
   PubMed Web of Science ®Google Scholar
• Mhatre AN, Trifiro MA, Kaufman M et al. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat. Genet.5, 184–188 (1993).
   PubMed Web of Science ®Google Scholar
• Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J. Clin. Endocrinol. Metab.82, 3777–3782 (1997).
   PubMed Web of Science ®Google Scholar
• Shah NA, Antoine HJ, Pall M, Taylor KD, Azziz R, Goodarzi MO. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J. Clin. Endocrinol. Metab.93, 1939–1945 (2008).
   PubMed Web of Science ®Google Scholar
• Kim JJ, Choung SH, Choi YM, Yoon SH, Kim SH, Moon SY. Androgen receptor gene CAG repeat polymorphism in women with polycystic ovary syndrome. Fertil. Steril.90, 2318–2323 (2008).
   PubMedGoogle Scholar
• Liu Q, Hong J, Cui B et al. Androgen receptor gene CAG(n) trinucleotide repeats polymorphism in Chinese women with polycystic ovary syndrome. Endocrine33, 165–170 (2008).
   PubMedGoogle Scholar
• Jaaskelainen J, Korhonen S, Voutilainen R, Hippelainen M, Heinonen S. Androgen receptor gene CAG length polymorphism in women with polycystic ovary syndrome. Fertil. Steril.83, 1724–1728 (2005).
   PubMed Web of Science ®Google Scholar
• Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J. Clin. Endocrinol. Metab.87, 161–165 (2002).
   PubMed Web of Science ®Google Scholar
• Hickey TE, Legro RS, Norman RJ. Epigenetic modification of the X chromosome influences susceptibility to polycystic ovary syndrome. J. Clin. Endocrinol. Metab.91, 2789–2791 (2006).
   PubMed Web of Science ®Google Scholar
• Franks SM, Mason H, White D, Willis D. Mechanisms of anovulation in polycystic ovary syndrome. In: The Ovary: Regulation, Dysfunction and Treatment. Filicori M, Flamigni C (Eds). Elsevier, Amsterdam, The Netherlands 183–186 (1996).
   Google Scholar
• Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum. Reprod. Update14, 367–378 (2008).
   PubMed Web of Science ®Google Scholar
• Tucci S, Futterweit W, Concepcion ES et al. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J. Clin. Endocrinol. Metab.86, 446–449 (2001).
   PubMed Web of Science ®Google Scholar
• Villuendas G, Escobar-Morreale HF, Tosi F, Sancho J, Moghetti P, San Millan JL. Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome. Fertil. Steril.79, 219–220 (2003).
   Google Scholar